CD38 and myelodysplastic syndrome: Altogether, these results indicated that the detection of a loss of CD38+HSPCs heterogeneity through entropy calculation is an attractive biomarker for predicting the outcome of MDS patients, including from early stage of the disease and for monitoring their follow-up.